Former Paras Pharma co-promoter Devendra Patel is back in the Rs 30,000 cr personal care market with his new brand Layer’r.

Former Former Paras Pharma co-founder Darshan Patel will launch nutraceuticals in the Indian market by 2012-end.

FMCG firm Emami Ltd is moving to a need-based advertising strategy rather than blanket promotions to improve profitability.

Marico has bought the personal care business of Paras Pharmaceuticals from UK consumer goods giant Reckitt Benckiser, edging out Emami.

Marico today acquired a part of the personal care business from Reckitt Benckiser India, which the domestic arm of the British major had bo...

Emami, Marico and Wipro Consumer are in the final lap to acquire Paras Pharma's 100-crore personal care business from Reckitt Benckiser.

All three prospective bidders are yet to receive an information memorandum from Reckitt Benckiser specifying details of the sale process.

While the absorption of Paras Pharma employees by Reckitt Benckiser has not been discussed yet, but a strong reason why Emami to acquire Ah...

It is an absolute shock,” says Emami Executive Chairman RS Agarwal about his company losing out to Reckitt Benckiser in the race to buy Par...

Reckitt Benckiser, maker of Dettol soaps, Harpic toilet cleaner and Vanish stain remover, outdid a number of contenders including Emami to ...

A leading UK-based company is all set to buy Ahmedabad-based Paras Pharmaceuticals, a person close to the development said.

Emami, which has shown a keen interest in Paras Pharma ever since the beginning of the bidding game, is understood to be shelling out aroun...

Taisho Pharmaceuticals has emerged as the front-runner to buy a majority stake in Paras Pharmaceuticals by offering over six times the annu...

Saugata Gupta, CEO - Consumer Products, Marico Ltd, spoke to ET Now on Marico looking at picking up controlling stake in Paras Pharma.

Some rival potential suitors of Ahmedabad-based Paras Pharmaceuticals are considering the option of co-bidding for the Rs 500-crore company...

Private equity firms Actis and Sequoia that together hold 70% stake are looking to sell their holding at an estimated price of $700 mn.

Wockhardt Pharma has just got into the game. The co is challenging Abbott Lab patent on epilepsy drug.